Latest News and Press Releases

NEW YORK, Dec. 21, 2004 (PRIMEZONE) -- Enhance Biotech, Inc. (Pink Sheets:EBOI), a specialty pharmaceutical company developing a portfolio of products focused on lifestyle drugs, and Ardent...

NEW YORK, Dec. 15, 2004 (PRIMEZONE) -- Bioaccelerate's (OTCBB:BACL) development partner Australian Cancer Technology ("AustCancer" ASX:ACU) today said it has initiated a Phase II clinical study of...

NEW YORK, Dec. 14, 2004 (PRIMEZONE) -- Bioaccelerate Holdings Inc. New York (OTCBB:BACL) and Faustus Forschungs Cie. Translational Cancer Research GmbH and Faustus Forschung Translational Drug...

NEW YORK and MONTREAL, Nov. 19, 2004 (PRIMEZONE) -- Bioaccelerate Inc. (OTCBB:BACL) and Supratek Pharma Inc. today announced the formation of a strategic alliance to develop and commercialise one of...

NEW YORK, Nov. 3, 2004 (PRIMEZONE) -- Bioaccelerate (OTCBB:BACL) portfolio company Enhance Biotech, Inc. (Pink Sheets:EBOI), a developer of a portfolio of products focused on lifestyle drugs,...

NEW YORK, Oct. 18, 2004 (PRIMEZONE) -- Innovate Oncology Inc. (OTCBB:IOVO), a Nevada corporation, today announced that it has closed the acquisition of Innovate Oncology Inc., a Delaware corporation...

NEW YORK, Oct. 11, 2004 (PRIMEZONE) -- Bioaccelerate Holdings, Inc. (OTCBB:BACL), a pharmaceutical development organization, today announced that one of its portfolio companies, CNSThera, a developer...

NEW YORK, Oct. 7, 2004 (PRIMEZONE) -- Bioaccelerate Holdings, Inc. (OTCBB:BACL), a pharmaceutical development organization, today announced that it will invest in Australian Cancer Technology...

NEW YORK, Oct. 6, 2004 (PRIMEZONE) -- Bioaccelerate Holdings, Inc. (OTCBB:BACL), a pharmaceutical development organization, today announced that it has appointed Bruce Murdoch as Head of its...

NEW YORK, Oct. 1, 2004 (PRIMEZONE) -- Enhance Biotech (EBOI) is announcing the commencement of recruitment this week of a definitive dose-ranging trial in preparation for Phase III of its premature...